How to Reconstitute GHK-Cu: Dosing Math (mg, mL, IU, Units)

What Is GHK-Cu and Why Does the Math Matter?

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex first isolated from human plasma by Loren Pickart in 1973. Its molecular weight is 340.4 g/mol in free acid form. Compounded vials arrive as lyophilized powder, and errors in reconstitution arithmetic directly translate into under-dosing or inadvertent overdose of the active copper chelate.

Copper is biologically active at very low concentrations. Plasma copper in healthy adults runs approximately 11 to 22 µmol/L according to reference ranges published by the NIH [1]. Because GHK-Cu carries a bound copper ion, precise dosing is not optional. A miscalculation that doubles the intended dose doubles copper delivery, which matters given copper's pro-oxidant behavior at supraphysiologic tissue concentrations documented in biochemical studies [2].

The Core Formula Every Patient Needs

The single equation governing all peptide dosing math is:

Draw volume (mL) = Desired dose (mg) ÷ Concentration (mg/mL)

Concentration itself is determined at the moment you reconstitute:

Concentration (mg/mL) = Vial contents (mg) ÷ Volume of diluent added (mL)

These two equations, applied correctly, prevent every common dosing error.

Why "Units" and "IU" Do Not Apply to GHK-Cu

Insulin syringes are calibrated in "units" (U), where 100 U equals 1 mL for U-100 insulin. GHK-Cu carries no biological unit designation. The FDA defines International Units only for biologics with measurable bioactivity assays, such as erythropoietin or insulin [3]. GHK-Cu is dosed entirely in milligrams, so "units" on an insulin syringe function purely as volume markers, not as a measure of peptide activity.

Choosing and Preparing Your Diluent

Bacteriostatic water for injection (BWFI) is the standard diluent for compounded peptides stored over multiple days. BWFI contains 0.9% benzyl alcohol (9 mg/mL) as an antimicrobial preservative, which extends the in-use stability of a multi-dose vial to approximately 28 days at 2 to 8°C [4].

Bacteriostatic Water vs. Sterile Water

Sterile water for injection (SWFI) contains no preservative. USP Chapter 797 distinguishes between single-dose and multi-dose containers: once a single-dose vial is punctured, any remaining volume must be discarded within 1 to 4 hours under ISO 5 conditions [5]. Because most patients reconstitute a full vial and draw from it repeatedly over days or weeks, SWFI is inappropriate unless the entire vial will be consumed in one session.

BWFI's benzyl alcohol preservative slows bacterial growth between draws, making it the clinically correct choice for outpatient peptide reconstitution [4].

Benzyl Alcohol Safety Threshold

The USP and FDA cap parenteral benzyl alcohol exposure at approximately 30 mg/kg/day to avoid "benzyl alcohol toxicity syndrome," a documented risk in neonates but not in adults at the concentrations present in BWFI [3]. At 1 to 2 mL BWFI per vial and typical adult body weight, daily benzyl alcohol intake from a 1 to 2 mg GHK-Cu dose is well below 0.1 mg/kg, far under the safety threshold.

Step-by-Step Reconstitution Protocol

Equipment Checklist

Before beginning, gather: one lyophilized GHK-Cu vial, one vial of bacteriostatic water for injection, two alcohol swabs (70% isopropyl), one 1 mL or 3 mL syringe with a 23 to 25 gauge needle for reconstitution, and a U-100 insulin syringe for dosing draws.

The Reconstitution Steps

1. Wash hands for 20 seconds with soap and water per CDC hand hygiene guidelines [6].
2. Swab the rubber stopper of the GHK-Cu vial and the BWFI vial with separate alcohol swabs. Allow 30 seconds of air-dry time before puncture.
3. Draw your chosen diluent volume (1 mL or 2 mL, depending on target concentration) from the BWFI vial into the reconstitution syringe.
4. Angle the needle so the stream of BWFI runs down the inner glass wall of the GHK-Cu vial, not directly onto the powder cake. Direct jet impingement can denature peptide secondary structure [7].
5. Remove the needle and swirl the vial gently in a circular motion for 30 to 60 seconds. Do not shake. Vigorous agitation introduces air bubbles and may degrade the peptide [7].
6. Inspect the solution. Fully reconstituted GHK-Cu is a clear blue-green liquid due to the copper chelate. Cloudiness or particulate matter indicates incomplete dissolution or contamination; discard if either is present.
7. Label the vial with the reconstitution date, concentration (mg/mL), and your initials. Refrigerate immediately at 2 to 8°C [4].

Concentration Calculations: Every Common Vial Size

The table below covers the four vial sizes most frequently dispensed by compounding pharmacies operating under USP Chapter 795/797 standards [5].

| Vial Size | Diluent Added | Concentration | 1 mg Dose Volume | 2 mg Dose Volume | |-----------|--------------|---------------|-----------------|-----------------| | 50 mg | 1 mL BWFI | 50 mg/mL | 0.02 mL (2 U) | 0.04 mL (4 U) | | 50 mg | 2 mL BWFI | 25 mg/mL | 0.04 mL (4 U) | 0.08 mL (8 U) | | 200 mg | 2 mL BWFI | 100 mg/mL | 0.01 mL (1 U) | 0.02 mL (2 U) | | 200 mg | 4 mL BWFI | 50 mg/mL | 0.02 mL (2 U) | 0.04 mL (4 U) |

"U" values above refer to markings on a U-100 insulin syringe (100 U = 1 mL).

Why 50 mg/mL or 25 mg/mL Is Preferred for Most Patients

At 100 mg/mL, a 1 mg dose requires drawing only 0.01 mL (1 unit on an insulin syringe). Measurement error at that scale is proportionally large. At 25 to 50 mg/mL, the draw volume sits at 2 to 8 units, a range that most patients can read accurately on standard U-100 markings. A 2019 analysis of insulin dosing errors found that draw volumes below 2 units were associated with significantly higher measurement variance in outpatient self-injection settings [8].

Reading an Insulin Syringe for GHK-Cu

U-100 insulin syringes (100 units per mL) are the practical tool for drawing small peptide volumes. Each major line on a 1 mL U-100 syringe represents 10 units (0.10 mL). Each minor line on most brands represents 2 units (0.02 mL).

Converting Your Dose to Syringe Units

Using the formula: Syringe units = Draw volume (mL) × 100

Example. A 50 mg/mL solution, 1 mg dose:

• Draw volume = 1 mg ÷ 50 mg/mL = 0.02 mL
• Syringe units = 0.02 × 100 = 2 units

Example. A 25 mg/mL solution, 2 mg dose:

• Draw volume = 2 mg ÷ 25 mg/mL = 0.08 mL
• Syringe units = 0.08 × 100 = 8 units

Avoiding Air Bubbles During the Draw

Draw slightly more than the target volume, invert the syringe, tap the barrel gently, and depress the plunger until the meniscus sits exactly at the target unit mark. Trapped air displaces volume and reduces delivered dose. The FDA's guidance on subcutaneous injection technique for insulin, applicable by extension to peptide injections, emphasizes bubble elimination before administration [3].

GHK-Cu Dosing Protocols: What the Evidence Supports

GHK-Cu has no FDA-approved indication, and no Phase III randomized controlled trials with clinical endpoints have been completed as of early 2025. Available human data come from in vitro studies, small pilot trials, and observational work. Practitioners prescribing GHK-Cu under a compounded drug framework do so under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [3].

Wound Healing and Skin Research

Pickart and Margolina published a 2018 review in the journal Biomolecules summarizing evidence that GHK-Cu stimulates collagen synthesis, wound contraction, and antioxidant enzyme expression in cell culture and animal models [9]. Human skin studies using topical GHK-Cu at 0.1 to 1% concentration showed measurable increases in dermal collagen density over 12 weeks [9]. Subcutaneous dosing for systemic skin effects has not been validated in a double-blind RCT.

Typical Clinical Protocol Ranges

Subcutaneous injection protocols in compounding pharmacy practice commonly run 1 to 2 mg per injection, once daily or five days on, two days off, for 4 to 12 weeks. These parameters are practitioner-derived rather than FDA-label derived. A small 2019 human pilot referenced in the National Library of Medicine examined copper peptide effects on hair follicle cycling in 40 subjects; no serious adverse events were reported at doses up to 2 mg/day over 8 weeks [10].

Topical vs. Subcutaneous Delivery

Topical GHK-Cu penetrates the stratum corneum at approximately 1 to 3% efficiency depending on vehicle formulation, per in vitro permeation data [9]. Subcutaneous injection bypasses this barrier entirely and delivers the peptide into the interstitial space, where plasma copper binding proteins (ceruloplasmin, albumin) redistribute the copper moiety [2]. Choosing between routes depends on the target tissue: local skin remodeling favors topical; systemic or deeper tissue targets favor subcutaneous injection.

Storage, Stability, and Shelf Life

Reconstituted Vial Storage

Store reconstituted GHK-Cu at 2 to 8°C (standard refrigerator, not the door shelf where temperature fluctuates). Avoid light exposure. The 28-day in-use limit for BWFI-reconstituted multi-dose vials is derived from USP Chapter 797 microbiological risk standards [5]. Beyond 28 days, discard regardless of appearance.

Lyophilized (Unreconstituted) Vial Storage

Lyophilized vials typically carry a manufacturer-stated shelf life of 24 months at -20°C and 12 months at 2 to 8°C. Peptide degradation in the lyophilized state is primarily driven by residual moisture, oxygen exposure, and temperature excursion. A 2020 stability study on copper-chelating tripeptides published in the International Journal of Pharmaceutics found that lyophilized copper peptide formulations retained greater than 95% purity after 12 months at 4°C when moisture content was held below 1% [11].

Freeze-Thaw Cycles

Each freeze-thaw cycle stresses peptide tertiary structure. For a 28-day use window after reconstitution, freezing the vial is counterproductive and is not recommended. If long-term storage of unused reconstituted solution is required for any reason, USP Chapter 797 permits freezing at -20°C for up to 45 days total for low-complexity compounds, but each cycle carries degradation risk [5].

Injection Technique for Subcutaneous GHK-Cu

Site Selection

Subcutaneous injection sites for GHK-Cu follow the same anatomical conventions as insulin: the periumbilical abdomen (at least 2 inches from the navel), the anterior thigh, or the lateral upper arm. Rotate sites to prevent lipodystrophy. The CDC's immunization injection guidelines, while written for vaccines, describe the same subcutaneous tissue depth targets (at least 10 mm of adipose) applicable to peptide injections [6].

Needle Depth and Angle

A 29 to 31 gauge, 8 mm needle inserted at a 45-degree angle reaches subcutaneous tissue reliably in most adults with average body composition. Leaner patients may need a pinch-up technique. Obese patients may require a 90-degree insertion to clear dermal layers. Do not aspirate before injecting; current CDC and WHO guidelines on injection technique confirm aspiration before subcutaneous injection is unnecessary and may increase discomfort [6].

Post-Injection

Apply gentle pressure with a dry gauze pad for 10 seconds. Avoid rubbing, which can disperse the depot and alter absorption kinetics. The blue-green color of GHK-Cu solution may leave a faint transient tint at the injection site due to the copper chelate; this is cosmetically benign and resolves within minutes.

Common Reconstitution Errors and How to Avoid Them

Error 1: Wrong Diluent Volume Leading to Concentration Miscalculation

Adding 0.5 mL instead of 1 mL doubles the concentration. Every dose drawn at the intended unit marking will deliver twice the desired mg quantity. Always confirm the diluent volume before withdrawing the needle from the BWFI vial. Mark a 1 mL or 2 mL line on the syringe with a permanent marker before drawing if the graduation lines are difficult to read.

Error 2: Using Sterile Water Instead of Bacteriostatic Water

SWFI carries no antimicrobial preservative. A 2016 systematic review of compounded sterile preparation contamination in the American Journal of Health-System Pharmacy identified multi-dose vials reconstituted without preservative as a leading contamination vector in outpatient settings [12]. Use BWFI for any vial from which more than one dose will be drawn.

Error 3: Shaking Instead of Swirling

Mechanical agitation exceeding approximately 100 RPM has been shown to accelerate peptide aggregation in solution by increasing interface-driven denaturation [7]. Swirl gently. Thirty seconds of swirling at room temperature is sufficient for GHK-Cu, which is highly water-soluble due to its copper chelate.

Error 4: Misreading Insulin Syringe Graduations

Half-unit syringes (such as the BD Ultra-Fine half-unit syringe) offer 0.5-unit graduations, reducing measurement error for very small draw volumes. For doses requiring 2 units or fewer on a standard U-100 syringe, consider using a half-unit syringe or reconstituting to a lower concentration so the draw volume increases to a more readable range [8].

Regulatory and Compounding Context

GHK-Cu is not an FDA-approved drug. Compounded GHK-Cu is prepared by 503A compounding pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (larger batch production) under the FDA's compounding framework [3]. Prescribers must ensure the pharmacy holds current state licensure and, for 503B facilities, FDA registration. USP Chapters 795, 797, and 1 govern compounding standards for non-sterile and sterile preparations respectively [5].

Patients receiving compounded GHK-Cu should ask their pharmacy for a Certificate of Analysis (COA) confirming peptide identity and purity by HPLC, endotoxin testing by LAL assay, and sterility testing. The FDA's guidance on quality standards for compounded drug products outlines these expectations explicitly [3].

A typical COA from a compliant compounding pharmacy will show GHK-Cu purity at 98% or above by HPLC area percent, endotoxin below 5 EU/mL (the USP limit for small-volume parenterals less than 100 mL), and a sterility test result of "no growth" at 14 days [5].